KANAGAWA, Japan–(BUSINESS WIRE)–PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan (Chairman: Patrick C. Reid, “PeptiDream”) (Tokyo: 4587) today announced that it has entered into a Research Collaboration and License Agreement with the US – based at Eli Lilly and Company (Lilly) focused on the discovery and development of new peptide drug conjugates (“PDCs”).
Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify high-affinity macrocyclic peptide ligands to targets of interest selected by Lilly, capable of delivering a Lilly-conjugated payload to specific cells and tissues of interest to Lilly. PeptiDream will lead the peptide discovery and optimization efforts, and Lilly will lead the payload discovery and optimization efforts. Lilly will be responsible for all development aspects of all PDC products resulting from the collaboration.
The new research collaboration and license agreement builds on a long collaborative relationship between the companies, with the first collaboration and license agreement in December 2013, followed by a non-exclusive license of PeptiDream’s proprietary PDPS technology in March 2016, which specifically excluded work on PDC programs.
Under the terms of the agreement, PeptiDream will receive an upfront payment from Lilly as well as be eligible for payments based on the achievement of certain development, regulatory and commercial milestones potentially totaling up to US$1.235 billion (¥163 billion*1). In addition, PeptiDream is eligible to receive royalties on net sales of any such products.
“I am pleased to announce this collaboration with Lilly and very much look forward to using our peptide discovery and optimization capabilities to generate peptide ligands capable of delivering Lilly payloads to specific cells and tissues to develop new and innovative PDC therapeutics for the treatment of disease. This collaboration builds on our efforts in the field of PDC and will allow us to further expand our range of innovative PDC therapies.” He said Patrick C. Reid PhD, President and CEO of PeptiDream.
*1: Currency conversion rate USD/JPY: 132
About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into an entirely new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream uses its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform that enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, to identify highly potent and selective macrocyclic peptide candidates, which can then be developed into therapeutics and diagnostics based on peptides, small molecules or peptide-drug conjugates (PDCs). PeptiDream has an extensive global network of discovery and development partners that drive the development and commercialization of a broad and diverse range of investigational therapies. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, visit www.peptiddream.com.